Contact this trialFirst, we need to learn more about you.
CDK4/6 Inhibitor
Abemaciclib + Bevacizumab for Recurrent Brain Cancer
Recruiting1 awardPhase < 1
Dallas, Texas
This trial found that the addition of Abemaciclib to Bevacizumab was safe in patients with recurrent Glioblastoma (GBM) and specific molecular aberrations. Adverse events were similar to those seen with Bevacizumab alone.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.